950220 — Neoimmunetech Income Statement
0.000.00%
- KR₩146bn
- KR₩88bn
Annual income statement for Neoimmunetech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 13.9 | 26.5 | 45.4 | 45 | 42.6 |
Operating Profit | -13.9 | -26.5 | -45.4 | -45 | -42.6 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -12.2 | -25.8 | -45.8 | -46.7 | -40.8 |
Provision for Income Taxes | |||||
Net Income After Taxes | -12.2 | -25.8 | -45.9 | -46.8 | -40.9 |
Net Income Before Extraordinary Items | |||||
Net Income | -12.2 | -25.8 | -45.9 | -46.8 | -40.9 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -12.2 | -25.8 | -45.9 | -46.8 | -40.9 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.748 | -1.56 | -2.4 | -2.37 | -2.07 |